계명대학교 의학도서관 Repository

Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study

Metadata Downloads
Author(s)
Dong Hyun SinnHye Won LeeYong-Han PaikDo Young KimYoon Jun KimKang Mo KimSi Hyun BaeJi Hoon KimYeon Seok SeoJae Young JangByoung Kuk JangHyung Joon YimHyung Joon KimByung Seok LeeBo Hyun KimIn Hee KimEun-Young ChoJung Il LeeKyung-Suk Suh
Keimyung Author(s)
Jang, Byoung Kuk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Digestive diseases and sciences
Issued Date
2020
Volume
66
Issue
1
Keyword
Hepatocellular carcinomaPortal vein invasionCohort
Abstract
Background and Aims:
Sorafenib is a proven first-line treatment recommended for hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI). However, multiple treatment modalities are used in clinical practice as a first-line option. This study is a prospective, observational, multicenter, cohort study evaluating patterns of treatment modalities and outcomes for HCC patients with PVI.

Methods:
The baseline characteristics, treatment modalities, and outcomes were prospectively collected for 287 newly diagnosed HCC patients with PVI between August 2015 and July 2016 from 16 sites in Korea.

Results:
During a median 7.8 months of follow-up (range 0.3–24.6 months), mortality was observed in 123 (42.9%) patients. Decision tree analysis classified patients into five subgroups with different outcomes. The patterns of treatment were very heterogeneous, and there was no dominant treatment modality. The most commonly used treatment modality was transarterial chemoembolization (TACE) (20.2%) followed by TACE plus external beam radiation therapy (17.8%) and sorafenib (12.5%). When stratified according to the extent of PVI, sorafenib treatment showed comparable outcomes when the PVI extent was lobal or main/bilateral, yet showed worse outcomes when the PVI extent was limited to the segmental level compared to those who received treatment other than sorafenib.

Conclusions:
HCC patients with PVI comprise a heterogeneous population and are treated with various treatment modalities with diverse clinical outcomes in clinical practice. Subclassification of HCC patients with PVI is required to minimize heterogeneity and should be considered for the selection of treatment modalities and future clinical trials.
Keimyung Author(s)(Kor)
장병국
Publisher
School of Medicine (의과대학)
Citation
Dong Hyun Sinn et al. (2020). Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study. Digestive diseases and sciences, 66(1), 315–324. doi: 10.1007/s10620-020-06134-4
Type
Article
ISSN
1573-2568
Source
https://link.springer.com/article/10.1007%2Fs10620-020-06134-4
DOI
10.1007/s10620-020-06134-4
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43056
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.